focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ark Therapeutics Amendment

1 Feb 2013 14:53

RNS Number : 9613W
D.A.A.Phillips
01 February 2013
 



 FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

D.A.A.Phillips/K.F.Phillips Aquaglow ltd

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Ark Therapeutics

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

30/1/'2013

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

YES/NO

If YES, specify which:

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary 1p

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

3,375,000

1.613

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

 

TOTAL:

3,375,000

1.613

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary 1p

 

 

Purchase

Purchase

purchase

500,000

635,065

875,000

1.10

0.95

0.95

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

 

none

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

none

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES/NO

 

 

 

31/1/2013

Contact name:

D.A.A.Phillips

Telephone number:

07775141617

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETUAOSROSAURAR
Date   Source Headline
6th Jun 20122:41 pmRNSBlocklisting Interim Review
18th May 201212:02 pmRNSHolding(s) in Company
18th May 201212:01 pmRNSDirector Dealings
18th May 201211:57 amRNSResult of AGM
17th May 20127:00 amRNSInterim Management Statement
16th May 20127:00 amRNSCompletion of Phase 1 Study
2nd May 20127:00 amRNSGrant and Patent Update
25th Apr 20127:00 amRNSRegulatory Approval of Manufacturing Suite
17th Apr 20122:36 pmRNSDirector/PDMR Shareholding
10th Apr 20127:00 amRNSNew Board Appointment
2nd Apr 20123:25 pmRNSAnnual Information Update
26th Mar 20127:00 amRNSChange of Broker Name
15th Mar 20124:09 pmRNSDirector/PDMR Shareholding
13th Mar 20124:16 pmRNSBoard Changes
12th Mar 20127:00 amRNSFinal Results
23rd Feb 20124:29 pmRNSHolding(s) in Company
9th Feb 201211:10 amRNSNotice of Results
8th Feb 20127:00 amRNSUS patent for Neuropilin-1 receptor
4th Jan 20127:00 amRNSManufacturing Update
7th Dec 201111:48 amRNSDirector/PDMR Shareholding
5th Dec 20112:35 pmRNSBlocklisting Interim Review
9th Nov 20117:00 amRNSInterim Management Statement
3rd Nov 20117:00 amRNSManufacturing agreement
16th Sep 20114:41 pmRNSSecond Price Monitoring Extn
16th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20117:00 amRNSRe Agreement
24th Aug 20115:29 pmRNSHalf Yearly Report on National Storage Mechanism
24th Aug 20117:00 amRNSHalf Yearly Report - Part 2
24th Aug 20117:00 amRNSHalf Yearly Report - Part 1
1st Aug 20114:31 pmRNSHolding(s) in Company
29th Jul 20114:40 pmRNSSecond Price Monitoring Extn
29th Jul 20114:35 pmRNSPrice Monitoring Extension
25th Jul 20114:40 pmRNSSecond Price Monitoring Extn
25th Jul 20114:35 pmRNSPrice Monitoring Extension
18th Jul 20113:10 pmRNSHolding(s) in Company
14th Jul 20117:00 amRNSWins ?5.3 million EU Framework Programme 7 Grant
6th Jul 20117:00 amRNSArk receives Finnish Grants
4th Jul 20117:00 amRNSGrant of US patents and milestone payments
13th Jun 20114:40 pmRNSSecond Price Monitoring Extn
13th Jun 20114:35 pmRNSPrice Monitoring Extension
3rd Jun 201111:57 amRNSBlocklisting Interim Review
17th May 20117:00 amRNSInterim Management Statement
9th May 20113:28 pmRNSAGM Results
31st Mar 20111:43 pmRNSAnnual Information Update
30th Mar 20111:08 pmRNSDirector/PDMR Shareholding
24th Mar 20113:40 pmRNSAnnual Financial Report
9th Mar 20117:00 amRNSFinal Results
3rd Mar 20117:00 amRNSAppointment of CFO
2nd Mar 20117:00 amRNSDisposal
28th Feb 201111:49 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.